A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

AIMS: The histone deacetylase inhibitor belinostat has activity in various cancers. Because belinostat is metabolized by the liver, reduced hepatic clearance could lead to excessive drug accumulation and increased toxicity. Safety data in patients with liver dysfunction are needed for this drug to r...

Descripción completa

Detalles Bibliográficos
Autores principales: Takebe, Naoko, Beumer, Jan H., Kummar, Shivaani, Kiesel, Brian F., Dowlati, Afshin, O'Sullivan Coyne, Geraldine, Piekarz, Richard, Rubinstein, Lawrence, Fogli, Laura K., Vaishampayan, Ulka, Goel, Sanjay, O'Bryant, Cindy L., El‐Rayes, Bassel F., Chung, Vincent, Lenz, Heinz‐Josef, Kim, Richard, Belani, Chandra P., Tuscano, Joseph M., Schelman, William, Moore, Nancy, Doroshow, James H., Chen, Alice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848909/
https://www.ncbi.nlm.nih.gov/pubmed/31271459
http://dx.doi.org/10.1111/bcp.14054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848909/
https://www.ncbi.nlm.nih.gov/pubmed/31271459
http://dx.doi.org/10.1111/bcp.14054

Ejemplares similares